Subject(s)
Cardiomyopathy, Restrictive , Heart Neoplasms , Hemangiosarcoma , Humans , Hemangiosarcoma/pathology , Hemangiosarcoma/complications , Hemangiosarcoma/diagnosis , Heart Neoplasms/pathology , Heart Neoplasms/complications , Heart Neoplasms/diagnostic imaging , Cardiomyopathy, Restrictive/pathology , Cardiomyopathy, Restrictive/etiology , Male , Middle Aged , Female , Fatal OutcomeABSTRACT
Primary cardiac angiosarcoma is a rare, aggressive malignancy that commonly metastasizes to various organs. The presenting symptoms are typically nonspecific, so a comprehensive examination is required to confirm the diagnosis promptly. This case report describes the presentation of an older patient with a history of neoplasms. Echocardiography and biopsy were performed, but despite surgical intervention to resect a large right atrial mass, the patient died. A final diagnosis of primary angiosarcoma was made based on the resected specimen.
Subject(s)
Heart Neoplasms , Hemangiosarcoma , Humans , Heart Neoplasms/diagnosis , Heart Neoplasms/surgery , Aged , Hemangiosarcoma/diagnosis , Hemangiosarcoma/surgery , Fatal Outcome , Biopsy , Male , Heart Atria/pathology , Heart Atria/diagnostic imaging , Heart Atria/surgery , Echocardiography , Cardiac Surgical Procedures/methodsABSTRACT
RATIONALE: Primary breast angiosarcoma is a rare tumor, accounting for only 0.05% of all malignant breast tumors. The primary breast angiosarcoma typically presents with nonspecific clinical manifestations, which can easily lead to misdiagnosis. Potential factors contributing to misdiagnosis include skin changes that may be erroneously attributed to breast trauma-induced bruising and breast swelling that may be mistaken for inflammatory diseases or other benign tumors. PATIENT CONCERNS: A 19-year-old female was admitted to the hospital due to repeated lump formation in the left breast for 9 months after left breast trauma. DIAGNOSES: The diagnosis of primary breast angiosarcoma was confirmed on hematoma biopsy. INTERVENTIONS: Due to the patient's condition, no special treatment was given postoperatively. After then, there was a recurrence in the chest wall, and the patient received 2 cycles of chemotherapy, resulting in a reduction in the size and lightening of the recurrent chest wall mass. When chemotherapy intolerance happened, the patient chose to discontinue treatment. OUTCOMES: After an 18-month follow-up, the recurrent chest wall mass increased and the patient died from bleeding. LESSONS: Primary breast angiosarcoma has a low incidence but high malignancy, with a high recurrence and metastasis rate, leading to a poor prognosis. The adjuvant chemotherapy, radiotherapy, targeted therapy, and other treatments should be considered to reduce the local recurrence rate and prolong patient survival.
Subject(s)
Breast Neoplasms , Hemangiosarcoma , Humans , Female , Hemangiosarcoma/diagnosis , Hemangiosarcoma/pathology , Hemangiosarcoma/therapy , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Breast Neoplasms/diagnosis , Young Adult , Neoplasm Recurrence, Local , Fatal OutcomeABSTRACT
INTRODUCTION: Primary pulmonary angiosarcoma (PPA) is a highly aggressive and rare malignancy originating from the endothelial cells of blood vessels in the lungs. PPA is an extremely rare subtype, with less than 30 cases reported to date. PPA is not only challenging to diagnose but also has a poor prognosis, often resulting in a high mortality rate within a year of diagnosis, regardless of the treatment approach. METHOD: We present the case of a 33-year-old woman with no significant past medical history who presented with abdominal pain and was incidentally found to have a right hilar mass with pleural effusion and empyema. After undergoing surgery for a perforated gastric ulcer, her pulmonary lesions were further worked up. Despite an extensive diagnostic evaluation, including imaging, bronchoscopy, and thoracotomy, establishing a diagnosis was challenging. Ultimately, PPA was diagnosed on surgical lung biopsy, and the patient was started on pazopanib and paclitaxel chemotherapy but expired after 1 month due to multiple complications. CONCLUSION: This case highlights the difficulty in diagnosing this rare tumor and its poor prognosis regardless of therapy. Greater awareness of PPA and more research are needed to improve early detection and treatment options for this deadly disease.
Subject(s)
Hemangiosarcoma , Incidental Findings , Lung Neoplasms , Humans , Hemangiosarcoma/diagnosis , Hemangiosarcoma/complications , Hemangiosarcoma/pathology , Female , Adult , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Lung Neoplasms/pathology , Fatal Outcome , Tomography, X-Ray Computed/methods , Bronchoscopy/methods , Pyrimidines/therapeutic use , Indazoles , Biopsy , Sulfonamides/therapeutic use , Paclitaxel/therapeutic use , Paclitaxel/administration & dosageABSTRACT
We describe an elderly patient presenting with pneumothorax, cystic lung disease and a scalp lesion. The pneumothorax resolved after placing a chest tube and suction but recurred within a week. Progression of cystic features was also seen, and biopsies of the lung and scalp lesions were performed. Immunohistochemistry was positive for markers of endothelial cells (CD31 and ERG) and negative for markers expected to be positive in alveolar cells (keratin AE1/AE3 and TTF-1), supporting the diagnosis of metastatic angiosarcoma. Palliative chemotherapy did not prevent progression and the patient expired soon after. In describing the clinico-radiological correlation of metastatic angiosarcoma, we also briefly describe the approach to cystic lung disease. Understanding the pathophysiology of cyst formation in metastatic angiosarcoma may help clinicians to better appreciate and manage the full spectrum of cystic lung disease, especially with atypical features.
Subject(s)
Hemangiosarcoma , Scalp , Humans , Scalp/pathology , Hemangiosarcoma/pathology , Hemangiosarcoma/complications , Fatal Outcome , Lung Neoplasms/pathology , Lung Neoplasms/complications , Lung Neoplasms/diagnosis , Male , Pneumothorax/etiology , Disease Progression , Cysts , Aged , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/diagnosis , Head and Neck Neoplasms/complicationsABSTRACT
Cutaneous angiosarcoma (CAS) is a rare aggressive malignancy that most commonly manifests in White men older than 60 years and often appears as an enlarging ecchymosis on the head, neck, or scalp. Surgery with negative margins is the first-line treatment. The role of Mohs micrographic surgery (MMS) is uncertain but can be used in smaller, well-circumscribed lesions on the head and neck. The greatest impact that dermatologists can have in the management of CAS is through a thorough total-body skin examination and heightened awareness resulting in a shortened time to diagnosis. Until quality evidence allows for the creation of consensus guidelines, multidisciplinary care at a cancer center that specializes in rare difficult-to-treat tumors is essential in optimizing patient outcomes.
Subject(s)
Hemangiosarcoma , Mohs Surgery , Skin Neoplasms , Humans , Hemangiosarcoma/diagnosis , Hemangiosarcoma/therapy , Hemangiosarcoma/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/therapy , Skin Neoplasms/pathology , MaleABSTRACT
This case report describes a 42-year-old woman with cutaneous angiosarcoma and venous malformation of the nasal tip.
Subject(s)
Hemangiosarcoma , Skin Neoplasms , Humans , Hemangiosarcoma/pathology , Hemangiosarcoma/diagnosis , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Male , Female , AgedABSTRACT
Left ventricular dysfunction in dogs after the administration of doxorubicin (DOX) has been extensively examined. However, the effects of DOX on right ventricular (RV) function remain unknown. Therefore, the present study investigated whether the chemotherapy treatment with DOX decreases RV function. Twelve dogs (five with multicentric lymphoma, four with hemangiosarcoma, two with thyroid cancer, and one with lung adenocarcinoma) that received at least two doses of DOX were prospectively enrolled. Echocardiography and the measurement of troponin I were performed prior to each administration of DOX and approximately one month after the last administration. Right ventricular function was assessed by the RV fractional area change and RV Tei index. Two (n=4), three (n=3), four (n=3), and five (n=2) doses of DOX were administered. While no significant differences were observed in the RV fractional area change, the RV Tei index was significantly impaired after two doses of DOX. Troponin I level significantly increased after four doses. Cumulative doses of DOX correlated with the RV Tei index (r=0.77, P<0.001). The present results demonstrated that the chemotherapy treatment with DOX decreased RV function in a dose-dependent manner in dogs.
Subject(s)
Antibiotics, Antineoplastic , Dog Diseases , Doxorubicin , Echocardiography , Troponin I , Animals , Dogs , Doxorubicin/administration & dosage , Dog Diseases/drug therapy , Male , Female , Antibiotics, Antineoplastic/therapeutic use , Troponin I/blood , Echocardiography/veterinary , Ventricular Function, Right/drug effects , Ventricular Dysfunction, Right/veterinary , Ventricular Dysfunction, Right/drug therapy , Lymphoma/veterinary , Lymphoma/drug therapy , Prospective Studies , Hemangiosarcoma/veterinary , Hemangiosarcoma/drug therapyABSTRACT
INTRODUCTION: While available systemic treatments have modest long term efficacy in advanced angiosarcoma, immunotherapy represents an interesting new therapeutic opportunity. To establish its benefit, it is required to conduct a clinical trial assessing its efficacy and toxicity compared to standard treatments. MATERIAL AND METHODS: This is a literature review from PubMed search. RESULTS: Several systemic treatments (chemotherapy and TKI) are currently used in advanced angiosarcoma with ORR ranging from 12.5 to 68 % and PFS from 2 to 7 months. However, few randomized trials, mainly phase II, has been conducted to compare these treatments. While most centers propose doxorubicin containing regimens or paclitaxel in 1st or 2nd line, a high heterogeneity of regimens administered in this setting is observed even across sarcoma specialized centers with no consensual standard treatment. Encouraging signals of immunotherapy activity have been reported in angiosarcoma from several retrospective and phase II studies assessing anti-PD1 either alone or in combination with anti CTLA4 or TKI. Although cutaneous and head and neck location seems to benefit more from immunotherapy, response may be observed in any angiosarcoma subtype. In sarcoma in general and AS in particular, no biomarker has been clearly established to predict the efficacy of immunotherapy: high tumor mutational burden and presence of tertiary lymphoid structures are under assessment. DISCUSSION: Even essential, developing a randomized clinical trial in AS struggles with the heterogeneity of the disease, the lack of consensual standard regimen, the uncertainty on optimal immunotherapy administration and the absence of established predictive biomarkers. CONCLUSION: International collaboration is essential to run randomized trial in advanced AS and asses the efficacy of immune therapy in this rare and heterogeneous disease.
Subject(s)
Hemangiosarcoma , Humans , Hemangiosarcoma/therapy , Hemangiosarcoma/drug therapy , Hemangiosarcoma/pathology , Immunotherapy/methods , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Randomized Controlled Trials as Topic , Clinical Trials as Topic , Immune Checkpoint Inhibitors/therapeutic useSubject(s)
Hemangiosarcoma , Pulmonary Artery , Pulmonary Embolism , Vascular Neoplasms , Humans , Hemangiosarcoma/complications , Hemangiosarcoma/pathology , Pulmonary Embolism/diagnostic imaging , Pulmonary Artery/diagnostic imaging , Pulmonary Artery/pathology , Vascular Neoplasms/complications , Vascular Neoplasms/diagnostic imaging , Vascular Neoplasms/pathology , Male , Middle Aged , Tomography, X-Ray Computed , FemaleABSTRACT
Hemangiosarcoma is an aggressive tumour that most frequently occurs in larger, middle-aged dogs of certain breeds. The spleen is the most commonly affected organ. The aim of this prospective therapy study was to evaluate the clinical effect of autologous, monocyte-derived dendritic cell (DC) therapy in canine hemangiosarcoma stage II after splenectomy. Dogs (n=452) diagnosed with splenic hemangiosarcoma that underwent splenectomy were enrolled. Of these, 42 dogs with stage II entered the DC therapy study. The median survival time for the total group of 42 dogs was 203 days. The median survival for the group (n=34) that received the full DC therapy (≥3 vaccines) was 256 days, with a 29â¯% one-year survival rate and a hazard ratio of 0.30, adjusted to age and bodyweight (P=0.010). We further observed a significant increase in DC yield after each application and demonstrated that DC yield at the beginning of treatment is significantly related to patient survival. While further evidence is needed, we conclude that autologous, monocyte-derived DC therapy is a viable alternative to standard treatment methods of canine splenic stage II hemangiosarcoma.
Subject(s)
Dendritic Cells , Dog Diseases , Hemangiosarcoma , Splenic Neoplasms , Animals , Dogs , Hemangiosarcoma/veterinary , Hemangiosarcoma/therapy , Dog Diseases/therapy , Splenic Neoplasms/veterinary , Splenic Neoplasms/therapy , Female , Male , Prospective Studies , Splenectomy/veterinary , Transplantation, Autologous/veterinaryABSTRACT
Angiosarcoma is a rare, aggressive soft-tissue sarcoma of endothelial origin that necessitates early recognition, diagnosis, and treatment. The most commonly reported presentation consists of violaceous patches and plaques on the head and neck of elderly white men, with fewer reports affecting patients with Skin of Color. Most cases of angiosarcoma are idiopathic and tend to recur locally with early metastasis, conferring a poor prognosis. We report a case of an 83-year-old Fitzpatrick skin type IV man who presented with a large violaceous-to-black mamillated plaque on the frontotemporal scalp that was clinically highly suggestive of cutaneous angiosarcoma. However, unrevealing histopathology complicated our diagnostic process and delayed management. Immunohistochemistry was invaluable in determining the diagnosis of angiosarcoma. Our case highlights the aggressive nature of cutaneous angiosarcoma, necessitating close clinicopathologic correlation to confirm the diagnosis and initiate treatment.
Subject(s)
Head and Neck Neoplasms , Hemangiosarcoma , Scalp , Skin Neoplasms , Humans , Hemangiosarcoma/pathology , Hemangiosarcoma/diagnosis , Male , Aged, 80 and over , Skin Neoplasms/pathology , Skin Neoplasms/diagnosis , Scalp/pathology , Head and Neck Neoplasms/pathology , Head and Neck Neoplasms/diagnosis , ImmunohistochemistryABSTRACT
PURPOSE: This study sought to investigate oncological outcomes and prognostic factors for patients with angiosarcomas (AS). METHODS: This single-center, retrospective cohort study, analyzed histopathologically confirmed AS cases. Primarily diagnosed, locally recurrent and metastatic AS were included. Overall survival (OS), local control (LC) and local progression-free survival (LPFS) were assessed by Kaplan-Meier estimator. Multivariable Cox regression analysis was performed to detect factors associated with OS and LPFS. RESULTS: In total, 118 patients with a median follow-up of 6.6 months were included. The majority presented with localized disease (62.7%), followed by metastatic (31.4%) and locally recurrent (5.9%) disease. Seventy-four patients (62.7%) received surgery, of which 29 (39.2%) were treated with surgery only, 38 (51.4%) with surgery and perioperative radiotherapy or chemotherapy, and 7 (9.4%) with surgery, perioperative radiotherapy and chemotherapy. Multivariable Cox regression of OS showed a significant association with age per year (hazard ratio (HR): 1.03, p = 0.044) and metastatic disease at presentation (hazard ratio: 3.24, p = 0.015). For LPFS, age per year (HR: 1.04, p = 0.008), locally recurrent disease at presentation (HR: 5.32, p = 0.013), and metastatic disease at presentation (HR: 4.06, p = 0.009) had significant associations. Tumor size, epithelioid components, margin status, and perioperative RT and/or CTX were not significantly associated with OS or LPFS. CONCLUSION: Older age and metastatic disease at initial presentation status were negatively associated with OS and LPFS. Innovative and collaborative effort is warranted to overcome the epidemiologic challenges of AS by collecting multi-institutional datasets, characterizing AS molecularly and identifying new perioperative therapies to improve patient outcomes.
Subject(s)
Hemangiosarcoma , Humans , Hemangiosarcoma/pathology , Hemangiosarcoma/therapy , Hemangiosarcoma/mortality , Female , Male , Middle Aged , Retrospective Studies , Aged , Prognosis , Adult , Aged, 80 and over , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/epidemiology , Young AdultABSTRACT
BACKGROUND: Dogs with retroperitoneal hemangiosarcoma (HSA) exhibit variable postoperative median survival times (MST). OBJECTIVE: To retrospectively evaluate the prognostic value of selected tumour-related factors, such as tumour size, rupture, invasion into adjacent tissue, involvement of lymph node and distant metastasis, they were analysed in dogs with retroperitoneal HSA. METHODS: Ten dogs with retroperitoneal HSA managed solely with surgical excision were reviewed and compared with spleen (71) and liver (9) HSA. The Kaplan-Meier method and log-rank analysis were used compare MSTs between factors. Multivariable Cox proportional-hazard analysis was used to compare differences between arising sites. RESULTS: Retroperitoneal HSA showed comparatively longer postoperative MST compared with that of spleen and liver HSA and demonstrated significantly longer MST (p = 0.003) for tumours ≥5 cm (195 days) than <5 cm (70 days). Spleen HSA revealed significantly shorter MSTs in involvement of distant lymph nodes (23 days) and distant metastasis (39 days) than those in negative (83 days, p = 0.002 and 110 days, p < 0.001, respectively). Liver HSA also revealed significantly shorter MST (16.5 days compared with 98 days, p = 0.003) for distant metastasis. Additionally, hazard ratios (HRs) and their forest plot for overall HSA revealed as poor prognostic factors, arising sites (spleen; HR 2.78, p = 0.016 and liver; HR 3.62, p = 0.019), involvement of distant lymph nodes (HR 2.43, p = 0.014), and distant metastasis (HR 2.86, p < 0.001), and as better prognostic factor of tumour size ≥5 cm (HR 0.53, p = 0.037). CONCLUSION: In combination with overall HSA, retroperitoneal HSA shows comparatively longer postoperative MST compared to spleen and liver HSA, associated with tumour size ≥5 cm suggesting better prognostic factor.
Subject(s)
Dog Diseases , Hemangiosarcoma , Retroperitoneal Neoplasms , Animals , Dogs , Hemangiosarcoma/veterinary , Hemangiosarcoma/pathology , Hemangiosarcoma/surgery , Hemangiosarcoma/mortality , Retrospective Studies , Dog Diseases/pathology , Dog Diseases/surgery , Dog Diseases/mortality , Male , Female , Retroperitoneal Neoplasms/veterinary , Retroperitoneal Neoplasms/pathology , Retroperitoneal Neoplasms/surgery , Retroperitoneal Neoplasms/mortality , Prognosis , Splenic Neoplasms/veterinary , Splenic Neoplasms/surgery , Splenic Neoplasms/pathology , Splenic Neoplasms/mortality , Liver Neoplasms/veterinary , Liver Neoplasms/mortality , Liver Neoplasms/surgery , Liver Neoplasms/pathologyABSTRACT
BACKGROUND: We report on a series of consecutive patients with localized radiation-associated angiosarcoma (RAAS) of the breast region (BR) treated at two Italian sarcoma reference centers. MATERIALS AND METHODS: We retrospectively reviewed all cases of primary, localized, resectable RAAS of the BR, treated at one of the two participating institutions from 2000 to 2019. Relapse-free survival (RFS) and overall survival (OS) were calculated. The prognostic role of several variables was investigated. A propensity score matched (PSM) analysis was carried out. RESULTS: Eighty-four patients were retrospectively identified. Nineteen out of 84 patients (22.6%) were pretreated with an anthracycline-based regimen for previous cancer. All patients but one underwent surgery, with 37/84 (44.1%) receiving surgery alone and 46/84 (54.8%) a multimodal approach: 18/84 (21.4%) received radiation therapy (RT) and 46/84 (54.9%) received chemotherapy. An anthracycline-based regimen was used in 10/84 patients (11.9%), while a gemcitabine-based regimen was used in 33/84 (39.3%). With a median follow-up of 51 months (interquartile range: 30-126 months), 36/84 patients (42.9%) relapsed and 35/84 patients (41.7%) died (8/84, 9.5% in the lack of metastatic disease). Five-year OS and 5-year RFS were 57% [95% confidence interval (CI) 43% to 68%] and 52% (95% CI 39% to 63%), respectively. Both (neo)adjuvant RT and chemotherapy were associated with better RFS [hazard ratio (HR) 0.25, 95% CI 0.08-0.83; HR 0.45, 95% CI 0.23-0.89] with a trend towards a better OS (HR 0.51, 95% CI 0.18-1.46; HR 0.60, 95% CI 0.29-1.24). Gemcitabine-based regimens seemed to perform better (HR 4.28, 95% CI 1.29-14.14). PSM analysis retained the above results. CONCLUSIONS: This retrospective study supports the use of (neo)adjuvant RT and chemotherapy, in primary, localized resectable RAAS of the BR. An effort to prospectively validate the role of (neo)adjuvant RT and chemotherapy is warranted.
Subject(s)
Breast Neoplasms , Hemangiosarcoma , Neoplasms, Radiation-Induced , Humans , Hemangiosarcoma/etiology , Hemangiosarcoma/therapy , Hemangiosarcoma/drug therapy , Retrospective Studies , Female , Middle Aged , Breast Neoplasms/radiotherapy , Breast Neoplasms/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/therapy , Breast Neoplasms/pathology , Aged , Neoplasms, Radiation-Induced/etiology , Adult , Treatment Outcome , Aged, 80 and overABSTRACT
Introduction: Renal haemangioma is a benign tumour, and due to its characteristics, it must be distinguished from malignant diseases. We present a clinical case of primary renal angiosarcoma initially mistaken for haemangioma due to their similarity. Case report: A 58-year-old man was admitted to the hospital with suspicion of pulmonary embolism. The patient complained of pain on the left side. An ultrasound and CT scan of the abdomen showed a tumour mass ~20.5 × 17.2 × 15.4 cm in size in the projection of the left kidney. On CT images, there were data for clear cell renal clear cell carcinoma (ccRCC). A left nephrectomy was performed. However, histological examination revealed renal haemangioma. Three months later, the patient presented to the hospital with abdominal and lumbar pain. A CT scan showed multiple small hypoechoic foci up to 2 cm in size in the liver, lungs, and intra-abdominally, with the most data for carcinosis. Histological re-verification of the left kidney showed a renal vascular tumour with pronounced signs of infarction and necrosis with the majority of the evidence supporting angiosarcoma. Despite treatment, the patient's outcome was fatal. Conclusions: Based on the clinical presentation, radiological images and histological examination data, the tumour was initially misdiagnosed as kidney haemangioma. Due to the rarity of this tumour, there are no established treatment protocols or clinical guidelines for managing primary kidney angiosarcoma.
Subject(s)
Hemangiosarcoma , Kidney Neoplasms , Humans , Male , Middle Aged , Hemangiosarcoma/diagnosis , Kidney Neoplasms/pathology , Kidney Neoplasms/diagnosis , Kidney Neoplasms/diagnostic imaging , Fatal Outcome , Tomography, X-Ray Computed , NephrectomyABSTRACT
BACKGROUND: Angiosarcoma is a sarcoma that occurs in a range of tissue types, and only rarely in the salivary glands, showing a predilection for the parotid glands of older patients. Preoperative diagnosis may be challenging, especially on cytology, with significant morphological overlap with high-grade primary salivary gland carcinomas. The molecular alterations of this rare salivary gland neoplasm are also not well-characterized. METHODS AND RESULTS: We present a case of right submandibular gland swelling in a 73-year-old male. On fine needle aspiration, including immunohistochemical stains on cell block, the tumor was initially diagnosed as poorly differentiated carcinoma. Resection of the submandibular gland revealed epithelioid angiosarcoma. We performed molecular work-up of the tumor, utilizing targeted next-generation sequencing, DNA methylation profiling and fluorescence in-situ hybridization. Histopathologic assessment revealed an infiltrative tumor comprising solid sheets of epithelioid cells. The tumor cells formed haphazardly anastomosing vascular channels with intracytoplasmic lumina containing red blood cells. On immunohistochemistry, the tumor cells were positive for CD31, CD34 and ERG. Approximately 40% of the tumor cells showed nuclear expression of GATA3. A pathogenic TP53 R267W mutation was detected on next-generation sequencing. DNA methylation analysis did not cluster the tumor with any known sarcoma type. Copy number analysis showed possible MYC amplification and CDKN2A losses, although only the latter was confirmed on fluorescence in-situ hybridization. CONCLUSION: Epithelioid angiosarcoma is an important differential diagnosis to high-grade salivary gland carcinoma. In particular, GATA3 expression may be encountered in both angiosarcoma and high-grade salivary gland carcinomas and cause diagnostic confusion. Identification of TP53 mutations and CDKN2A losses suggest shared oncogenic pathways with soft tissue angiosarcomas, and should be further investigated.
Subject(s)
Hemangiosarcoma , Submandibular Gland Neoplasms , Humans , Male , Aged , Hemangiosarcoma/genetics , Hemangiosarcoma/pathology , Hemangiosarcoma/diagnosis , Submandibular Gland Neoplasms/pathology , Submandibular Gland Neoplasms/genetics , Submandibular Gland Neoplasms/diagnosis , Biomarkers, Tumor/analysis , Biomarkers, Tumor/genetics , CytologyABSTRACT
BACKGROUND: This study aims to describe a rare case of primary ureteral hemangiosarcoma, in which surgical intervention preserved the kidney and ureter after tumor removal. CASE PRESENTATION: A 13-year-old, neutered male dog, weighing 14 kg, mixed-breed, presented with apathy, anorexia, acute-onset vomiting, and abdominal discomfort during the physical examination. Ultrasonography and pyelography revealed a right-sided dilation of the renal pelvis and ureter due to complete obstruction in the middle third of the ureter. A mass obstructing the lumen of the right ureter was completely resected, and ureteral suturing was performed, preserving the integrity of the involved structures. Histopathology confirmed primary ureteral hemangiosarcoma. Due to the local and non-invasive nature of the mass, chemotherapy was not initiated. The patient's survival was approximately two years, and normal renal function was preserved throughout this period. CONCLUSIONS: Considering this type of tumor in the differential diagnosis of upper urinary tract obstructive disorders. Furthermore, the preservation of the ureter and kidney is a suitable therapeutic option after surgical resection of non-invasive tumors.
Subject(s)
Dog Diseases , Hemangiosarcoma , Ureteral Neoplasms , Animals , Male , Dogs , Hemangiosarcoma/veterinary , Hemangiosarcoma/complications , Hemangiosarcoma/surgery , Dog Diseases/surgery , Ureteral Neoplasms/veterinary , Ureteral Neoplasms/complications , Ureteral Neoplasms/surgery , Ureteral Neoplasms/pathology , Paraplegia/veterinary , Paraplegia/etiology , Paraplegia/surgery , Ureteral Obstruction/veterinary , Ureteral Obstruction/surgeryABSTRACT
Primary cardiac angiosarcomas are extremely rare, highly aggressive tumours with rapid progression and high metastatic capability. More than 60% of tumours are detected after the onset of a metastatic disease. In the two cases presented, we demonstrate the role of muti-modality imaging in the diagnosis of the lesion and provide valuable input in prognosticating the disease burden. In both cases, the diagnosis was suspected initially by imaging, based on radiological observations, before the final histopathology confirmation was made. Positron emission tomography- (PET-CT) was a critical component of the diagnostic workup for the detection of disease extent and volume of total disease burden. Hence, PET-CT imaging should be performed in all aggressive appearing cardiac tumours. In view of misleading clinical presentation, we suggest that aggressive workup to be performed in suspected patients. Young patients presenting with vague symptoms and those with recurrent, unresolving, unexplained pericardial effusion deserves special consideration.